HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 30 Jan 2018 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
- 26 Jul 2017 Results assessing safety and pharmacokinetics, presented at the 9th International AIDS Society Conference on HIV Science.